僅用于工業(yè)應(yīng)用或科學(xué)研究,不可用于人類或動物的臨床診斷或治療,非藥用. Mavezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902)